Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 13/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.48 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL950740 | 1.00 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3KDM1AP2RX7 | |
| SCHEMBL5968212 | 0.90 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3KDM1A | |
| SCHEMBL31532355 | 0.89 | P2RX7 (0.46) | SLC6A2SLC6A4SLC6A3P2RX7IDO1 | |
| SCHEMBL8266958 | 0.86 | SLC6A4 (0.46) | SLC6A2SLC6A4SLC6A3KDM1AP2RX7 | |
| SCHEMBL4488371 | 0.82 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4749429 | 0.82 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20767115 | 0.82 | SLC6A4 (0.52) | SLC6A2SLC6A4SLC6A3EPHX2 | |
| SCHEMBL951983 | 0.81 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3KDM1AP2RX7 | |
| SCHEMBL951982 | 0.81 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3KDM1AP2RX7 | |
| SCHEMBL25570743 | 0.77 | BCHE (0.56) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868014-B2 | 1-(hetero)aryl-3-amino-pyrrolidine derivatives for use as mGluR3 antagonists | ELI LILLY AND COMPANY (US) | 2011-01-11 | — | — | US | disclosed |
| EP-1805165-B1 | 1-(HETERO)ARYL-3-AMINO-PYRROLIDINE DERIVATIVES FOR USE AS MGLUR3 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-12-16 | — | — | EP | disclosed |
| US-20080300266-A1 | 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists | ELI LILLY AND COMPANY (US) | 2008-12-04 | — | — | US | disclosed |
| EP-1805165-A1 | 1-(HETERO)ARYL-3-AMINO-PYROLLIDINE DERIVATIVES FOR USE AS MGLUR3 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006044454-A1 | 1-(HETERO)ARYL-3-AMINO-PYROLLIDINE DERIVATIVES FOR USE AS MGLUR3 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300266-A1 | 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists | GRM3, GRM1, GRIA3 | SLC6A2 1059/4885SLC6A4 437/4885SLC6A3 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.